HHL-B:CA:TSX-Harvest Healthcare Leaders Income ETF (CAD)

ETF | Others |

Last Closing

CAD 9.19

Change

+0.04 (+0.44)%

Market Cap

N/A

Volume

1.50K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

+0.07 (+0.26%)

CAD 6.19B
XEQT:CA iShares Core Equity Portfolio

+0.24 (+0.70%)

CAD 5.85B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

+0.03 (+0.05%)

CAD 5.48B
PHYS-U:CA Sprott Physical Gold Trust

N/A

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.45 (+1.20%)

CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

+0.30 (+0.67%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

N/A

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

N/A

CAD 3.29B
ZMMK:CA BMO Money Market Fund ETF Seri..

N/A

CAD 2.98B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.01 (-0.04%)

CAD 2.78B

ETFs Containing HHL-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.61% 39% F 40% F
Dividend Return 7.59% 90% A- 90% A-
Total Return 15.20% 50% F 51% F
Trailing 12 Months  
Capital Gain 7.36% 38% F 38% F
Dividend Return 8.25% 89% A- 91% A-
Total Return 15.61% 49% F 49% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.20% 52% F 45% F
Dividend Return 3.52% 52% F 40% F
Total Return 0.32% 68% D+ 26% F
Risk Return Profile  
Volatility (Standard Deviation) 5.63% 78% C+ 90% A-
Risk Adjusted Return 62.48% 79% B- 74% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike